Abstract
The effect of cannabinoid drugs (i.p.) on cold/restraint stress-induced gastric ulcers was studied in rats. The cannabinoid receptor agonist (WIN 55,212-2, 0.1-1 mg/kg), but not the less active isomer WIN 55,212-3 (1 mg/kg), reduced gastric ulceration. The protective effect of WIN 55,212-2 (1 mg/kg) was counteracted by the cannabinoid CB1 receptor antagonist SR141716A, but not by the cannabinoid CB2 receptor antagonist SR144528. These results indicate that the antiulcer effect of the cannabinoid receptor agonist WIN 55,212-2 is mediated by cannabinoid CB1 receptors.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Benzoxazines
-
Camphanes / pharmacology
-
Camphanes / therapeutic use
-
Male
-
Morpholines / pharmacology
-
Morpholines / therapeutic use*
-
Naphthalenes / pharmacology
-
Naphthalenes / therapeutic use*
-
Piperidines / pharmacology
-
Piperidines / therapeutic use
-
Pyrazoles / pharmacology
-
Pyrazoles / therapeutic use
-
Rats
-
Rats, Wistar
-
Receptor, Cannabinoid, CB2*
-
Receptors, Cannabinoid
-
Receptors, Drug* / drug effects
-
Receptors, Drug* / physiology
-
Rimonabant
-
Stomach Ulcer / drug therapy*
-
Stomach Ulcer / pathology
-
Stress, Physiological / pathology
Substances
-
Benzoxazines
-
Camphanes
-
Cnr2 protein, rat
-
Morpholines
-
Naphthalenes
-
Piperidines
-
Pyrazoles
-
Receptor, Cannabinoid, CB2
-
Receptors, Cannabinoid
-
Receptors, Drug
-
SR 144528
-
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
-
Rimonabant